Skip to main content
SpringerLink
Log in

Neue psychoaktive Substanzen

Synthetische Opioide: hohes psychisches und physisches Risiko

  • Zertifizierte Fortbildung Psychiatrie
  • Published:
InFo Neurologie + Psychiatrie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. United Nations Office on Drugs and Crimes (UNODC) World Drug Report 2016. https://www.unodc.org/wdr2016/

  2. Aktories K, Förstermann U, Hofmann FB, Starke K (Hrsg): Allgemeine und spezielle Pharmakologie und Toxikologie, Urban & Fischer Verlag, München 2006

  3. Lippert H (Hrsg): Anatomie, München 2003

  4. Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 2016; 3: 760-73

  5. Madras BK. The surge of opioid use, addiction, and overdoses: Responsibility and response of the US health care system. JAMA Psychiatry 2017; 74: 441-2

  6. Center for Behavioral Health Statistics and Quality. Results from the 2011 National survey on drug use and health: summary of national findings (HHS publication No. SMA 12-4713, NSDUH series H-44)

  7. Han B, Compton WM, Jones CM et al. Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003-2013. JAMA 2015; 314: 1468-78

  8. Centers for Disease Controls National Vital Statistics System. Multiple cause of death file. Atlanta (GA): Centers for Disease Control and Prevention; 2012

  9. Cheatle M. Facing the challenge of pain management and opioid misuse, abuse and opioid-related fatalities. Exp Rev Clin Pharmacol 2016; 9: 751-4

  10. Grant BF, Saha TD, Ruan WJ et al. Epidemiology of DSM-5 drug use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. JAMA Psychiatry 2016; 73: 39-47

  11. Wilkerson RG, Kim HK, Windsor TA et al. The opioid epidemic in the United States. Emerg Med Clin N Am 2016; 34: e1-e23

  12. Jones CM. Frequency of prescription pain reliever nonmedical use: 2002-2003 and 2009-2010. Arch Intern Med 2012; 172: 1265-7

  13. Paulozzi L, Jones C, Mack K et al. Centers for Disease Control and Prevention (CDC). Vital signs: Overdoses of prescription opioid analgesics—United States, 1999-2008. MMWR Morb Mortal Wkly Rep 2011; 60: 1487-92

  14. https://www.cdc.gov/mmwr/volumes/69/wr/mm6911a4.htm

  15. https://www.cdc.gov/drugoverdose/images/epidemic/2018-3-Wave-Lines-Mortality.png)

  16. Murray CJL, Vos T, Lozano R et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197-223

  17. Degenhardt L, Whiteford HA, Ferrari AJ et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet 2013; 382: 1564-74

  18. EMCDDA. European Drug Report 2018. https://www.emcdda.europa.eu/edr2018_en.

  19. Bastigkeit M, Weber B (Hrsg): Suchtmedizinische Grundversorgung. Thieme Verlag, Stuttgart, New York, 2019

  20. Leitlinien der Dt. Ges. f. Suchtforschung und Suchttherapie (DG-Sucht) und der Dt. Ges. f. Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN)

  21. Fareed A, Vayalapalli S, Casarella J et al. Effect of buprenorphine dose on treatment outcome. Journal of addictive diseases 2012; 31: 8-18

  22. Hser YI, Evans E, Huang D et al. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction 2016; 111: 695-705

  23. Soyka M, Pogarell O. Neue Slow-release-Buprenorphinformulierungen zur Optimierung der Opioidsubstitution. Nervenarzt 2019; 90: 932-7

  24. Dennis BB, Bawor M, Thabane L et al. Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis. PLoS One 2014; 9: e86114

  25. Yang HC, Chu SK, Huang CL et al. Genome-wide pharmacogenomic study on methadone maintenance treatment identifies SNP rs17180299 and multiple haplotypes on CYP2B6, SPON1, and GSG1L associated with plasma concentrations of methadone R- and S-enantiomers in heroin-dependent Patients. PLoS Genet 2016; 12: e1005910

  26. Crist RC, Ambrose-Lanci LM, Vaswani M et al. Case-control association analysis of polymorphisms in the delta-opioid receptor, OPRD1, with cocaine and opioid addicted populations. Drug Alcohol Depend 2013; 127: 122-8

Download references

Author information

Authors and Affiliations

  1. Klinik f. Psychiatrie u. Psychotherapie\/Tagesklinik, Nussbaumstraße 7, 80336, München, Germany

    Kristina Adorjan

  2. Klinik für Psychiatrie und Psychotherapie der, Nußbaumstr. 7, 80336, München, Germany

    Oliver Pogarell

Authors
  1. Kristina Adorjan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Oliver Pogarell
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrags von keinen wirtschaftlichen Interessen haben leiten lassen und im Zusammenhang mit diesem Beitrag keine Interessenkonflikte bestehen.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung.

Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adorjan, K., Pogarell, O. Synthetische Opioide: hohes psychisches und physisches Risiko. InFo Neurologie 23, 38–47 (2021). https://doi.org/10.1007/s15005-021-1823-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15005-021-1823-x

Search

Navigation